Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue 3, 2008, Pages 428-431

  Le, T ^a,b   Hopkins, L ^a   Baines, K A ^a   Rambout, L ^a   Fung Kee Fung, M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Platinum resistant; Toxicities; Weekly topotecan

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DEMOGRAPHY; DRUG TOLERABILITY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KAPLAN MEIER METHOD; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; TREATMENT RESPONSE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 43449116042     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01041.x     Document Type: Article

References (13)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993 329 : 1550 9.
2. Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001 40 : 340 60.
3. Vandenput I, Amant F, Neven P et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2007 17 : 83 7.
4. Levy T, Inbar M, Menczer J et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004 95 : 686 90.
5. O'Malley DM, Azodi M, Makkenchery A et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005 98 : 242 8.
6. Bhoola SM, Coleman RL, Herzog T et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004 95 : 564 9.
7. Traina TA, Sabbatini P, Aghajanian C, Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004 95 : 235 41.
8. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 92 : 205 16.
9. Le T, Leis A, Pahwa P et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol Oncol 2004 92 : 839 44.
10. Ledermann JA, Wheeler S. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer? Cancer Invest 2004 22 (Suppl. 2 2 10.
11. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol 2005 3 : 723 36.
12. Vasey PA. Management of recurrent epithelial ovarian carcinoma. Aust N Z J Obstet Gynaecol 2005 45 : 269 77.
13. Kurihara M, Sakamoto H, Ohta Y et al. Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women. Gan To Kagaku Ryoho 2001 28 : 55 61.